This resulted in a marked increase in the ratio of both CD4+ and CD8+ ICOS+ Teff to ICOS+ Tregs in the tumor/lungs and periphery in mice receiving MVA-BN-HER2 treatment compared to control mice (Fig. 6d, e). This evidence concerns the gene CD4 and neoplasm.